SeaSpine has been acquired by Integra LifeSciences Holdings for US$89 million in cash, subject to certain post-closing adjustments. After the combination, the spine and orthobiologics portfolio is now the largest component of Integra’s orthopaedics revenue category.
“SeaSpine is an ideal strategic fit for Integra, as the combination brings together two well-respected innovators in the spinal fusion market,” said Stuart Essig, CEO, Integra. “Integra has a track record of successfully executing on and integrating strategic transactions, and we expect to realise the benefits of this combination in both our top line growth and earnings per share over the long-term.”
SeaSpine develops and distributes a full range of spinal fixation products, including both hardware and biologics. Products are offered to customers across the US and in select markets in Europe.
Integra LifeSciences is a world leader in medical devices, dedicated to limiting uncertainty for surgeons so they can concentrate on providing the best patient care. It offers innovative solutions in orthopaedics, neurosurgery, spine, reconstructive and general surgery.